ZAI LAB LIMITED Cash and Cash Equivalents, Period Increase (Decrease)
ZAI LAB LIMITED (ZLAB) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$166.71 million for the 12-month period ending 2018-12-31, per its 20-F filed 2019-03-29.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-03-29
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|
| 2018-12-31 | -$166.71M 20-F · filed 2019-03-29 |
| 2017-12-31 | $145.71M 20-F · filed 2019-03-29 |
| 2016-12-31 | $70.79M 20-F · filed 2019-03-29 |
| 2015-12-31 | $6.01M 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |